Highlights:

• ZEPZELCA^® (lurbinectedin) is the first new therapy approved to treat second-line metastatic SCLC in Australia in more than 20 years
• ZEPZELCA approval granted under a provisional regulatory pathway
• US FDA and TGA collaborated via 'Project Orbis' to accelerate availability to Australian patients
• Important advance for adult patients whose...